SUBSTITUTED QUINAZINE DERIVATIVES AS FGFR-KINASE INHIBITORS FOR TREATMENT OF CANCER Russian patent published in 2016 - IPC C07D403/04 A61K31/502 A61P35/00 

FIELD: pharmaceutics.

SUBSTANCE: invention is related to compounds of formula I, pharmaceutical compositions based thereon, use thereof for treating cancer, FGFR-kinase mediated, and methods of their production. In general formula I n is any integer, equal to 0, 1 or 2; R¹ is C_1-6alkyl; each group R^1a represents hydrogen; each group R² is C_1-4alkoxy; R^3a is-NR¹⁰R¹¹, hydroxyl, gidroksiC_1-6alkyl, cianoC_1-6alkyl, C_1-6alkyl substituted R⁹, C_1-6alkyl substituted -NR¹⁰R¹¹, C_1-6alkyl substituted hydroxyl and -NR¹⁰R¹¹, C_1-6alkyl substituted -C(=O)-NR¹⁰R¹¹; R^3b is hydrogen or hydroxyl; provided that if R^3a is -NR¹⁰R¹¹, then R^3b is hydrogen; or R^3a and R^3b are taken together to form =O, to make cyclopropyl together with carbon atom, with which they are bonded or to make =CH-C_0-4alkyl, substituted R^3c; R^3s is-NR¹⁰R¹¹ or cyano; R⁹ is a 5-7-member monocyclic heterocyclic ring, containing at least one heteroatom, selected from N, O or S, where 5-7-member monocyclic heterocyclyl is optionally substituted = O; R¹⁰ and R¹¹ group each independently represents hydrogen, C_1-6alkyl, C_1-6alkyl substituted-NR¹⁴R¹⁵, or halogenC_1-6alkyl; R¹⁴ and R¹⁵ group each independently denotes hydrogen or C_1-4alkyl.

EFFECT: treatment of cancer.

34 cl, 4 tbl, 10 ex